Not applicableActive Not RecruitingNCT07063316What this trial is testingSGLT2 Inhibitors and Renal Anemia in Japan: RWDWho this might be right forChronic Kidney Disease Boehringer Ingelheim 15,000
Testing effectiveness (Phase 2)Study completedNCT06888505What this trial is testingDapagliflozin to Prevent Anthracycline-Induced CardiotoxicityWho this might be right forAnthracyclines-Induced CardiotoxicityCardiotoxicity Hawler Medical University 94
Testing effectiveness (Phase 2)Study completedNCT05884866What this trial is testingInvestigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.Who this might be right forChronic Renal FailureMechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte HomeostatisChronic Kidney Disease Stage 3+1 more Klinikum Nürnberg
Large-scale testing (Phase 3)Looking for participantsNCT07025629What this trial is testingDapagliflozin for Cardio-renal Protection After ICU DischargeWho this might be right forHeart Failure and Chronic Kidney Disease Post-ICU Assistance Publique - Hôpitaux de Paris 600
Testing effectiveness (Phase 2)Looking for participantsNCT06845163What this trial is testingRandomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients With Diabetic Macular EdemaWho this might be right forDiabetic Macular EdemaCenter-involved Diabetic Macular Edema Alexandria University 56
Testing effectiveness (Phase 2)Study completedNCT04907214What this trial is testingSGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity PilotWho this might be right forObesityPre-diabetes Vanderbilt University Medical Center 29
Testing effectiveness (Phase 2)Not Yet RecruitingNCT03867487What this trial is testingSGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseaseWho this might be right forNon-Alcoholic Fatty Liver DiseaseNAFLDPediatric NAFLD Justin Ryder 40
Post-approval studies (Phase 4)UnknownNCT02501616What this trial is testingEffect of Dapagliflozine on Systemic and Renal Endothelial FunctionWho this might be right forEndothelial FunctionType 2 Diabetes Seoul National University Hospital 22
Post-approval studies (Phase 4)UnknownNCT06350487What this trial is testingThe Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection FractionWho this might be right forHeart Failure, Preserved Ejection Fraction Samsung Medical Center 154
Not applicableStudy completedNCT05966792What this trial is testingSGLT2 Inhibitors in Treating Patients With PCOSWho this might be right forPolycystic Ovary Syndrome Shanghai 10th People's Hospital 82
Not applicableUnknownNCT05934071What this trial is testingEffects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.Who this might be right forHeart FailureVentricular RemodelingVentricular Dysfunction Fondazione Policlinico Universitario Agostino Gemelli IRCCS 160
Not applicableStudy completedNCT02500186What this trial is testingThe Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) InhibitorWho this might be right forDiabetes Melltius, Type 2 Kansai Electric Power Hospital 24
Post-approval studies (Phase 4)Study completedNCT05152940What this trial is testingERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEFWho this might be right forHeart Failure With Reduced Ejection FractionCongestion Icahn School of Medicine at Mount Sinai 28
Large-scale testing (Phase 3)Study completedNCT03968224What this trial is testingEffectiveness of Dapagliflozin for Weight LossWho this might be right forPreDiabetesObesity, MorbidDiabetes Mellitus, Type 2 Centro Medico Nacional Siglo XXI IMSS 160
Large-scale testing (Phase 3)Active Not RecruitingNCT06297603What this trial is testingEffect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)Who this might be right forType 2 Diabetes Eli Lilly and Company 320
Post-approval studies (Phase 4)UnknownNCT06442280What this trial is testingSGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HFWho this might be right forHeart Failure AcuteDiabetes Type 2Heart Failure With Reduced Ejection Fraction+1 more University of Palermo 544
Post-approval studies (Phase 4)Study completedNCT04238702What this trial is testingRenohemodynamic Effects of Combined empagliflOzin and LosARtanWho this might be right forDiabetes Mellitus, Type 2Diabetic Kidney Disease Amsterdam UMC, location VUmc 24
Post-approval studies (Phase 4)Looking for participantsNCT06249945What this trial is testingEMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal DiseaseWho this might be right forHeart Failure With Preserved Ejection FractionEnd Stage Renal Disease on Dialysis National Taiwan University Hospital 150
Not applicableLooking for participantsNCT06473844What this trial is testingEfficacy of SGLT2 Inhibitors in Adults With SepsisWho this might be right forSepsisInflammationSGLT2 Inhibitors+2 more Hospital Authority, Hong Kong 60
Not applicableActive Not RecruitingNCT05944432What this trial is testingCGM Use in Adults With Type 2 Diabetes on Basal InsulinWho this might be right forDiabetes Mellitus, Type 2 Abbott Diabetes Care 469